Zentalis Pharmaceuticals (NASDAQ:ZNTL) Earns “Buy” Rating from HC Wainwright

Zentalis Pharmaceuticals (NASDAQ:ZNTL)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $20.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 476.37% from the stock’s current price. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q3 2025 earnings at ($0.67) EPS and Q4 2025 earnings at ($0.68) EPS.

Several other equities analysts have also commented on the company. Wedbush upgraded Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 target price for the company in a research note on Monday, August 12th. Oppenheimer restated an “outperform” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $10.00.

Zentalis Pharmaceuticals Price Performance

ZNTL stock opened at $3.47 on Friday. The company’s 50 day simple moving average is $3.42 and its 200-day simple moving average is $5.42. Zentalis Pharmaceuticals has a 12 month low of $2.66 and a 12 month high of $18.07. The firm has a market capitalization of $247.27 million, a PE ratio of -1.39 and a beta of 1.74.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36. As a group, sell-side analysts anticipate that Zentalis Pharmaceuticals will post -2.81 earnings per share for the current year.

Institutional Trading of Zentalis Pharmaceuticals

Large investors have recently modified their holdings of the business. ProShare Advisors LLC boosted its holdings in Zentalis Pharmaceuticals by 9.0% in the first quarter. ProShare Advisors LLC now owns 15,436 shares of the company’s stock valued at $243,000 after purchasing an additional 1,274 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Zentalis Pharmaceuticals by 20.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock valued at $54,999,000 after acquiring an additional 585,644 shares in the last quarter. Kennedy Capital Management LLC bought a new stake in shares of Zentalis Pharmaceuticals in the 1st quarter worth about $189,000. Opaleye Management Inc. acquired a new stake in shares of Zentalis Pharmaceuticals in the 1st quarter valued at about $3,152,000. Finally, SG Americas Securities LLC acquired a new position in Zentalis Pharmaceuticals in the second quarter worth about $58,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.